- Details
- Ruchika Talwar interviews Kristian Stensland about his publication in Urology Practice on the size and scope of urologic oncology clinical trials. Dr. Stensland discusses their analysis of trials registered on clinicaltrials.gov since 2007, revealing that over 100 patients enroll daily in urologic oncology trials, totaling about 28,000 participants annually. Despite this significant number, enroll...
|
- Details
- Rahul Aggarwal presents findings on targeting DLL3 in neuroendocrine prostate cancer. He explains that DLL3 is highly expressed in high-risk neuroendocrine prostate cancer, particularly in the treatment-emergent form seen after androgen deprivation therapy. This Phase 1b study expanded on prior research in small cell lung cancer and included 40 patients with broad inclusion criteria for DLL3 posit...
|
- Details
- Diane Newman interviews Siobhan Sutcliffe about a project funded as part of the White House Moonshot Initiative. This project aims to gather more data to support PSA-based risk-stratified screening for prostate cancer. By using a man's PSA value, the research seeks to determine whether he might develop clinically significant prostate cancer that could potentially shorten his lifespan. The study in...
|
- Details
- Rana McKay and Sumanta (Monty) Pal join Zach Klaassen in discussing the Southern California Genitourinary (GU) Cancer Research Forum, a program aimed at uniting healthcare professionals in Southern California to coordinate research and patient care in GU cancers. The program highlights include discussions on kidney cancer, bladder cancer, and prostate cancer, integrating patient advocates and show...
|
- Details
- The METANOVA Trial investigates treating oligometastatic prostate cancer with metastasis-directed radiotherapy (MDRT) in addition to standard systemic and prostate-directed therapy. MDRT, using targeted radiation on all metastatic sites, aims to extend the time until cancer returns and potentially improve patient survival. Related Content: ClinicalTrials.gov Identifier: NCT06150417 Metastasis-dire...
|
- Details
- ESCAPE Trial design is described in this 3-minute explainer video. The ESCAPE trial is titled Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr and is a study for prostate cancer patients considering active surveillance to delay treatment. Traditionally, PSA tests, biopsies, and MRI scans monitor cancer. How...
|
- Details
- Alicia Morgans interviews Neha Vapiwala about the innovative phase three INDICATE trial, supported by the ECOG-ACRIN Group and NCI designated cooperative groups. The trial focuses on patients with biochemical recurrence after prostatectomy, examining the impact of PET scans on treatment decisions. It categorizes patients based on PET scan results: those without detectable cancer outside the pelvis...
|
- Details
- Zach Klaassen hosts Michael Hofman and Renu Eapen to discuss the LuTectomy trial, published in European Urology. The trial explores the use of Lutetium-PSMA-617 as a neoadjuvant treatment in prostate cancer surgery. Initially, the trial included both radiation and surgical arms, but later focused solely on the surgical approach. The study enrolled high-risk prostate cancer patients, with 20 partic...
|
- Details
- Emmanuel Antonarakis joins Alicia Morgans in a conversation about the trial in progress multicenter, open-label, randomized phase 3 ECLIPSE trial comparing the safety and efficacy of 177Lu-PSMA-I&T versus standard-of-care hormone therapy in patients with metastatic castration-resistant prostate cancer, previously treated with only one ARAT and are taxane-based chemo naive. The ECLIPSE trial is bei...
|
- Details
- Jones Nauseef speaks with Alicia Morgans about a trial in progress dose-escalation study of fractionated 225Ac-J591 for progressive metastatic castration-resistant prostate cancer (mCRPC) in patients with prior treatment with 177Lu-PSMA. With the approval of Lutetium 177 Jones Nauseef explains that the study team decided to modify the study design to include a post-177-Lu-PSMA cohort because patie...
|
